All In Biotech

Drug Trial Radar · NCT07046923

A Study of LY4175408 in Participants With Advanced Cancer

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Jul 28, 2025

Primary completion

Jul 2030

Study completion Jul 2030

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jul 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Small Cell Lung Carcinoma
  • Endometrial Neoplasms
  • Neoplasm Metastasis
  • Triple Negative Breast Cancer

Interventions

  • LY4175408Drug

    IV infusion

  • PembrolizumabDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • CisplatinDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408Time frame: 1 Cycle (21 days)
  2. Phase 1b-Overall Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)Time frame: Baseline up to approximately 4 years

Locations

24 sites in 5 countries. Site status is shown where the registry gives one.

  • Stanford Medicine Cancer Center

    Stanford, California

  • Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute

    Orlando, Florida

  • Florida Cancer Specialists - Sarasota

    Sarasota, Florida

  • The University of Chicago Medical Center (UCMC)

    Chicago, Illinois

  • Community Health Network

    Indianapolis, Indiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • John Theurer Cancer Center At Hackensack UMC

    Hackensack, New Jersey

  • Columbia University

    New York, New York

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York

  • The Ohio State University (OSU) Wexner Medical Center

    Columbus, Ohio

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • START Mountain Region

    West Valley City, Utah

  • NEXT Virginia

    Fairfax, Virginia

  • Centre Leon Berard

    Lyon, France

  • Institut Gustave Roussy

    Villejuif, France

  • Kyoto University Hospital

    Kyoto, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

  • Cancer Institute Hospital of JFCR

    Tokyo, Japan

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.